Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29830717 | 1.00 | NR1H2 (0.33) | NR1H2NR1H3IDO1RORCCES2 | |
| SCHEMBL984942 | 0.98 | NR1H2 (0.34) | NR1H2NR1H3IDO1RORCCES2 | |
| SCHEMBL18315374 | 0.98 | NR1H2 (0.34) | NR1H2NR1H3IDO1RORCCES2 | |
| SCHEMBL29831166 | 0.96 | NR1H2 (0.33) | NR1H2NR1H3IDO1RORCCES2 | |
| Silver SCHEMBL29830991 | 0.96 | NR1H2 (0.33) | NR1H2NR1H3IDO1RORCCES2 | |
| SCHEMBL1451396 | 0.96 | NR1H2 (0.33) | NR1H2NR1H3IDO1RORCCES2 | |
| Lithium Ion SCHEMBL29830873 | 0.96 | NR1H2 (0.33) | NR1H2NR1H3IDO1RORCCES2 | |
| Lithium Ion SCHEMBL1452309 | 0.96 | NR1H2 (0.33) | NR1H2NR1H3IDO1RORCCES2 | |
| Silver SCHEMBL1452073 | 0.96 | NR1H2 (0.33) | NR1H2NR1H3IDO1RORCCES2 | |
| SCHEMBL1451577 | 0.94 | NR1H2 (0.36) | NR1H2NR1H3RORCNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1034196-B1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | PROMERUS LLC (US) | 2005-01-12 | — | — | EP | claimed |
| US-6455650-B1 | CONTACTING POLYCYCLOOLEFIN MONOMER WITH A HIGH ACTIVITY GROUP 10 TRANSITION METAL CATALYST COMPLEX TO OBTAIN POLYMER PRODUCT | THE B.F. GOODRICH COMPANY | 2002-09-24 | — | — | US | claimed |
| US-20020052454-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-05-02 | — | — | US | claimed |
| US-20240279251-A1 | Monomer, Polymerizable Composition, and Polymers Derived Therefrom | 3M INNOVATIVE PROPERTIES COMPANY | 2024-08-22 | — | — | US | disclosed |
| WO-2024095078-A1 | COMPOSITIONS INCLUDING A MIXTURE OF ISOMERS OF ITACONIMIDE NORBORNENE AND CITRACONIMIDE NORBORNENE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240002586-A1 | CURABLE COMPOSITIONS, COMPOSITE FOAM, METHOD OF MAKING THE SAME, AND ARTICLE INCLUDING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY | 2024-01-04 | — | — | US | disclosed |
| US-7910674-B2 | Especially a copolymer of norbornene and/or alkylnorbornene and (trialkoxysilylalkyl)norbornene; optical articles such as ophthalmic lenses, wave guides, optical fibers, and optical adhesives | PROMERUS, LLC (US) | 2011-03-22 | — | — | US | disclosed |
| US-6936672-B2 | Mold addition polymerization of norbornene-type monomers using group 10 metal complexes | SUMITOMO BAKELITE CO., LTD. (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1155057-B1 | IN MOLD ADDITION POLYMERIZATION OF NORBORNENE-TYPE MONOMERS USING GROUP 10 METAL COMPLEXES | SUMITOMO BAKELITE CO (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-6903171-B2 | Polymerized cycloolefins using transition metal catalyst and end products thereof | PROMERUS, LLC (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1034196-B1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | PROMERUS LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030181607-A1 | Polymerized cycloolefins using transition metal catalyst and end products thereof | SUMITOMO BAKELITE CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| US-20030120006-A1 | In mold addition polymerization of norbornene-type monomers using group 10 metal complexes | THE B.F. GOODRICH COMPANY | 2003-06-26 | — | — | US | disclosed |
| US-6538087-B2 | (hetero)polycyclic polymer | PROMERUS, LLC | 2003-03-25 | — | — | US | disclosed |
| US-20030023013-A1 | Catalyst and methods for polymerizing cycloolefins | THE B.F.GOODRICH COMPANY | 2003-01-30 | — | — | US | disclosed |
| US-6455650-B1 | CONTACTING POLYCYCLOOLEFIN MONOMER WITH A HIGH ACTIVITY GROUP 10 TRANSITION METAL CATALYST COMPLEX TO OBTAIN POLYMER PRODUCT | THE B.F. GOODRICH COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020103317-A1 | Polymeric compositions for forming optical waveguides; optical waveguides formed therefrom; and methods for making same | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-08-01 | — | — | US | disclosed |
| US-20020064896-A1 | Optical waveguides and methods for making the same | 3M INNOVATIVE PROPERTIES COMPANY | 2002-05-30 | — | — | US | disclosed |
| US-20020052454-A1 | CATALYST AND METHODS FOR POLYMERIZING CYCLOOLEFINS | SUMITOMO BAKELITE CO., LTD. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6350832-B1 | CATALYTIC COSSLINKING POLYMER OF POLYCYCLOOLEFIN MONOMER, MOLDING AND SHAPING IN THE PRESENCE OF GROUP 10 TRANSITION METAL AND ANION | THE B. F. GOODRICH COMPANY | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279251-A1 | Monomer, Polymerizable Composition, and Polymers Derived Therefrom | PBRM1, CARM1, WASF2 | NR1H2 3334/4885NR1H3 3383/4885IDO1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.